MERTK and melanoma: Moreover, although melanoma cell lines resistant to single-agent MEKi did not upregulate MerTK (Supplementary Figure S1J), ∼30% (1 out of 3) paired human melanomas with acquired resistance to combined BRAFi+MEKi therapy showed elevated MerTK expression (Figures 1E, supplemental Table S2.1).